This company listing is no longer active
ChromoGenics Valuation
Is CHRO undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CHRO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate CHRO's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate CHRO's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CHRO?
Other financial metrics that can be useful for relative valuation.
| What is CHRO's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | n/a |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.8x |
| Enterprise Value/EBITDA | -0.1x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does CHRO's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.7x | ||
POLY Polyplank | 0.7x | n/a | SEK 18.2m |
ECC B Ecoclime Group | 0.3x | 7.1% | SEK 93.4m |
BALCO Balco Group | 0.7x | 18.0% | SEK 976.1m |
FMM B FM Mattsson | 1.2x | n/a | SEK 2.3b |
CHRO ChromoGenics | 7x | 53.0% | SEK 5.6m |
Price-To-Sales vs Peers: CHRO is expensive based on its Price-To-Sales Ratio (7x) compared to the peer average (0.8x).
Price to Earnings Ratio vs Industry
How does CHRO's PE Ratio compare vs other companies in the European Building Industry?
Price-To-Sales vs Industry: CHRO is expensive based on its Price-To-Sales Ratio (7x) compared to the European Building industry average (0.9x).
Price to Sales Ratio vs Fair Ratio
What is CHRO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 7x |
| Fair PS Ratio | 0.2x |
Price-To-Sales vs Fair Ratio: CHRO is expensive based on its Price-To-Sales Ratio (7x) compared to the estimated Fair Price-To-Sales Ratio (0.2x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.